<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03264768</url>
  </required_header>
  <id_info>
    <org_study_id>s60207</org_study_id>
    <nct_id>NCT03264768</nct_id>
  </id_info>
  <brief_title>Endoscopic Long Volume Reduction by Endobronchial Valves in Belgium</brief_title>
  <acronym>BEVA</acronym>
  <official_title>Endoscopic Long Volume Reduction by Endobronchial Valves in Belgium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This a single center non-randomised non-sham controlled intervention study evaluating the
      effectiveness and safety of endoscopic lung volume reduction by endobronchial valves
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the current study is to explore the effect of targeted lobar
      endobronchial lung volume reduction in symptomatic patients with severe emphysema and absent
      collateral ventilation, on lung function, exercise capacity and physical activity.
      Exploratory objectives are to extend insight in the clinical characteristics of responders
      and non-responders and to address relationships between lung function response, physical
      functioning and its impact on inflammation, skeletal and cardiac function.

      The study will also explore if treatment response can be optimised by an intermediate
      evaluation with CT scan one month after intervention. Endoscopic evaluation and repositioning
      of the endobronchial valves will be imposed in case no lober atelectasis is visualised.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>response rate of FEV1 at 3 months post intervention</measure>
    <time_frame>3 months</time_frame>
    <description>proportion of patients with a minimal change of FEV1 &gt; 100 ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate on SGRQ at 3 months and 6 months post intervention</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>proportion of patients with a minimal change of -4 points on SGRQ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate on 6 minutes walking distance (6MWD) at 3 months and 6 months post intervention</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>proportion of patients with a minimal improvement of 30 meters on 6MWD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate on residual volume (RV) at 3 months and 6 months post intervention</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>proportion of patients with a minimal reduction of 400 ml on residual volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate on FEV1 at 6 months post intervention</measure>
    <time_frame>6 months</time_frame>
    <description>proportion of patients with a minimal change of FEV1 &gt; 100 ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate on Transitional dyspnee index (TDI) at 3 months and 6 months post intervention</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>proportion of patients with a minimal change of -1 point on TDI</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in FEV1 (liters), FVC (liters), RV (liters), TLC (liters) at 3 and 6 months post intervention</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>Absolute difference from baseline values (liters)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in RV/TLC ratio (%) at 3 and 6 months post intervention</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>Absolute difference from baseline values (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in 6MWD (meters) at 3 and 6 months post intervention</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>Absolute difference from baseline values (meters)</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in physical activity at 3 and 6 months post intervention</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>Absolute difference in stepcounts per day (n) from baseline values</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in ProActive clinical visit questionnaire</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>Absolute difference in points from baseline values</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in BODE index</measure>
    <time_frame>3 months and 6 months post intervention</time_frame>
    <description>Absolute difference in points from baseline values</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard care in case collateral ventilation is observed (by Chartis)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endobronchial valves</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endobronchial valves in case collateral ventilation is absent (by Chartis)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>endobronchial valves</intervention_name>
    <description>A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.</description>
    <arm_group_label>Endobronchial valves</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 40 - 75 years

          -  Confluent or destructive heterogeneous emphysema on CT

          -  Smoking cessation for at least 6m (proven by urinary cotinine levels)

          -  FEV1 &lt; 60 %predicted, RV &gt; 150 %predicted, TLC &gt; 90 %predicted

          -  RV/TLC ratio ≥ 0.55

          -  6MWD &lt; 450 meter

          -  mMRC ≥ 2

          -  Visual estimation of 70% complete fissure between target lobe and adjacent lobe on CT
             of referring physician

          -  LABA-LAMA bronchodilator therapy as a minimum therapy

          -  Able to sign informed consent

        Exclusion Criteria:

          -  Homogenous emphysema

          -  PaCO2 &gt; 60 mmHg with ambient air

          -  PaO2 &lt; 45 mmHg with ambient air

          -  Previous LVRS, lung transplantation, lobectomy

          -  TLCO or FEV1 &lt; 20% predicted

          -  Significant pulmonary hypertension (PaPsyst &gt; 50 mm Hg)

          -  Heart failure with reduced EF (&lt; 40%)

          -  6MWD &lt; 100 meter

          -  BODE index ≥ 7 and eligible for transplantation

          -  Active cancer

          -  Life expectancy &lt; 3 months

          -  Significant lung disease other than COPD/emphysema

          -  Unable to comply with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim Janssens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital Leuven, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dooms Christophe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospial Leuven, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Denaux, sc, nurse</last_name>
    <phone>016 34 19 66</phone>
    <phone_ext>0032</phone_ext>
    <email>karen.denaux@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristien De Bent, sc</last_name>
    <phone>016 34 17 01</phone>
    <phone_ext>0032</phone_ext>
    <email>krisiten.debent@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Flanders</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2017</study_first_submitted>
  <study_first_submitted_qc>August 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Wim Janssens</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>valves</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>endoscopic long volume reduction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

